SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-007197
Filing Date
2024-05-08
Accepted
2024-05-08 08:01:37
Documents
61
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q avbp-20240331x10q.htm   iXBRL 10-Q 932421
2 EX-31.1 avbp-20240331xex31d1.htm EX-31.1 15724
3 EX-31.2 avbp-20240331xex31d2.htm EX-31.2 15718
4 EX-32.1 avbp-20240331xex32d1.htm EX-32.1 7766
5 EX-32.2 avbp-20240331xex32d2.htm EX-32.2 7760
  Complete submission text file 0001558370-24-007197.txt   4412821

Data Files

Seq Description Document Type Size
6 EX-101.SCH avbp-20240331.xsd EX-101.SCH 31307
7 EX-101.CAL avbp-20240331_cal.xml EX-101.CAL 26861
8 EX-101.DEF avbp-20240331_def.xml EX-101.DEF 117961
9 EX-101.LAB avbp-20240331_lab.xml EX-101.LAB 304949
10 EX-101.PRE avbp-20240331_pre.xml EX-101.PRE 236929
65 EXTRACTED XBRL INSTANCE DOCUMENT avbp-20240331x10q_htm.xml XML 646373
Mailing Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269
Business Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 240-780-6356
ArriVent BioPharma, Inc. (Filer) CIK: 0001868279 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41929 | Film No.: 24924309
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)